The European Medicines Agency (EMA) announced today that it has recommended the approval of the CF drug Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
Site Search
As an adult with cystic fibrosis, I know just how powerful and creative the CF community can be. That's why I'm excited to announce the four 2017 Impact Grant awardees who are making a positive impact on the CF community.
The CF Adult and Family Advisors (AFA) just got a fresh new look and name: Community Voice. By joining this group, people with cystic fibrosis and their family members have an active say in the Cystic Fibrosis Foundation's initiatives, driving improvements that benefit everyone impacted by CF.
On Aug. 27, leaders from the Cystic Fibrosis Foundation, along with several people from the CF community, participated in a virtual public meeting hosted by the Institute for Clinical and Economic Review to provide insights and expertise on the value of CFTR modulators.